- 初创公司ImagOworks和Sibel以新颖的健康技术解决方案认可，这些解决方案利用了旨在改善疾病的检测，预防和治疗的艺术智能，几何建模和生物整合的传感器
sEOUL, KOREA, 5 November 2019- Janssen Korea Ltd.和Johld乐动nson＆Johnson Innovation LLC与首尔都市政府和韩国健康行业发展研究所（Khidi）合作，今天宣布了获奖者智慧创新Quickfire挑战智能医疗保健在首尔生物医学国际会议上。
这获奖者，，，，Imakoworksand Sibel, Inc.,will receive combined grant funding totalingKRW150,000,000（约134,000美元）[1]，在首尔生物枢纽居住了一年，由约翰逊和约翰逊家族的科学，技术和商业化专家获得指导和教练，并获得了JLABS全球企业家社区的访问。乐动体育意甲直播
- Imakoworks：基于首尔的KIST衍生公司Imaworks，在其创新的3D医疗/牙科软件平台中应用人工智能和几何建模技术，旨在改善手术结果。
- sibel, Inc.:Illinois-basedsibel, Inc. is developing breakthrough, bio-integrated sensors with the potential to allow for full vital signs monitoring in patients of all ages and sizes.
“亚太地区是创新的温床，专注于生命科学的企业家在努力将自己的思想带入商业化时面临许多障碍。”沙龙·陈（Sharon Chan），Jlabs @上海的负责人，Johnson＆Johnson Innovation - Jlabs[2]。“目的智慧创新Quickfire挑战智能医疗保健is to identify and help to accelerate promising early-stage health tech innovations with the potential to make a long-lasting, positive impact on health. With our collaborators, we aim to provide these innovators with the resources and mentoring needed to advance their ideas into breakthrough solutions for patients in Korea and around the world.”
这智慧创新Quickfire挑战智能医疗保健was launched in July 2019 to鼓励global entrepreneurs, researchers, students, and innovators to submit ideas for the following technology-enabled innovation areas:
- 大数据，人工智能，区块链
- 3D printing, Internet of Things (IoT), sensors, wearables
- 个性化医学，伴侣诊断
“The quality of the QuickFire Challenge applications we received reflects the tremendous innovative spirit and breadth of expertise within the life science ecosystem across Korea,”said珍妮郑，区域董事总经理詹森北亚[3]。“We are proud to name ImagoWorks and Sibel Inc. thesmart Healthcare QuickFire Challenge awardeesand look forward to supporting their health tech innovations.”
这QuickFire Challenges are managed by Johnson & Johnson Innovation – JLABS,
一个“无弦的”全球孵化器网络，并寻求增强和启用开创性的科学和健康解决方案。
有关QuickFire挑战的更多信息，请访问：乐动体育为什么赞助西甲//m.2574design.com/quickfire-challenges。
＃＃＃
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive, all with no strings attached. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit:www.jnjinnovation.com。
About Johnson & Johnson Innovation – JLABS
Johnson & Johnson Innovation-JLABS（JLABS）是一个全球开放创新生态系统的网络，在广泛的医疗保健范围内促进并赋予创新者，包括药品，医疗设备，消费者和健康技术领域，以创建和加速生命，生命增强，生命增强健康，健康和保健的健康，保健和保健，保健和保健，保健和保健健康，保健和保健技术领域。对世界各地患者的解决方案。JLABS通过为新兴公司提供最佳环境来实现这一点明天的突破性医疗解决方案。在JLABS，我们重视伟大的想法，并热衷于消除成功的障碍，以帮助创新者释放其早期科学发现的潜力。JLABS是一个无弦的模型，这意味着企业家可以在坚持其知识产权的同时自由发展科学。JLABS还发表了Quickfire挑战运动，以寻求最好的科学。有关更多信息，请访问www.m.2574design.comor follow@JLABS。
关于约翰逊和约翰逊的詹森制药公司
在Janssen，我们正在创造一个疾病过去的未来。我们是Johnson＆Johnson的制药公司，不懈地努力，通过与科学作斗争，以独创性的方式与疾病作斗争，并充满内心的绝望，使各地的患者成为现实。我们专注于可以使最大差异的医学领域：心血管和新陈代谢，免疫学，传染病和疫苗，神经科学，肿瘤学和肺动脉高压。了解更多信息www.janssen.com。跟随我们www.twitter.com/JanssenGlobal。Janssen Korea Ltd.是Johnson＆Johnson的Janssen制药公司之一。
[1]From the KRW150 million grant, each awardee will receive a KRW 75 million grant including one-year mandatory residency, which must be used toward the rent and utilities at the Seoul Bio Hub for a year.
[2]Sharon Chan受雇于Johnson＆Johnson（香港）有限公司。
[3]珍妮郑（Jenny Zheng）受雇于詹森·韩国有限公司（Janssen Korea Ltd.）
